- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Cate Lockhart, PharmD, PhD: Biosimilar vs Generic Markets
Cate Lockhart, PharmD, PhD, discusses the similarities and differences in the biosimilar and generic markets.
Transcript
How does the biosimilar market compare to that of generics?
Certainly, with the regulatory pathway, to me, that’s where it diverges. Beyond that, I don’t see it as really being divergent. If you think about biosimilars— if they are approved as a biosimilar– that means they are significantly similar. It’s not identical, you know, because it’s a biologic, but it needs to be substantially similar and [have] no clinical difference.
In a sense, in spite of the regulatory process, there’s no evidence of any clinically meaningful difference. In that sense, the divergence really is post-regulatory, in my opinion, where it’s a matter of education among prescribers, patients, [and] payers, but then in the United States that’s not really the hurdle for utilization.
So, I don’t know that this necessarily diverges from the generics scenario other than it is certainly a scenario that we did not fully appreciate would come to pass in that, the reason for slow uptake in the United States is not wholly because of concerns about safety and effectiveness. It’s more tactical on the part of pharmaceutical companies— these are business decisions, this is a business– and that’s perfectly fine. But, the effect is creating a marketplace where even though we now have 11 approved [biosimilar] products in the US, only 3 are currently on the market.
That’s a place where it diverges from generics in a way, although, we did see similar problems with generics [such as] slow uptake of generics back in the day because of the uncertainty.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
